+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allergy Vaccine Market by Vaccine Type, Route of Administration, Allergens Targeted, Technology, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Allergy Vaccine Market by Vaccine Type, Route of Administration, Allergens Targeted, Technology, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Allergy Vaccine Market by Vaccine Type, Route of Administration, Allergens Targeted, Technology, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4905049
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allergy Vaccine Market is projected to reach USD 1.79 Billion in 2026. It is expected to continue growing at a CAGR of 13.58%, reaching USD 3.90 Billion by 2032.

Allergy vaccines, clinically known as allergen immunotherapy, are disease-modifying treatments designed to retrain immune tolerance to allergens such as grass pollen, ragweed, house dust mite, tree pollen, molds, and animal dander. The allergy vaccine market spans subcutaneous immunotherapy, sublingual immunotherapy tablets and drops, standardized allergen extracts, diagnostic-linked prescribing, and long-term adherence services.

Demand is supported by a large and persistent disease burden. ARIA and WAO guidance commonly cites allergic rhinitis affecting 10% to 30% of adults and up to 40% of children, while WHO estimates asthma affected 262 million people and caused 455,000 deaths in 2019. Because allergic rhinitis and asthma frequently coexist, allergy vaccines are increasingly positioned as a strategic intervention to reduce symptoms, medication dependence, and long-term disease progression.

Transformative Shifts in the Allergy Vaccine Landscape

The allergy vaccine landscape is shifting from symptom control toward precision, prevention-oriented respiratory care. Longer pollen seasons, urban air pollution, indoor allergen exposure, and rising patient awareness are increasing demand for durable therapies beyond antihistamines, corticosteroids, and rescue medications. A 2021 PNAS analysis found North American pollen seasons lengthened by about 20 days and pollen concentrations rose 21% from 1990 to 2018, reinforcing the climate-health link.

Commercial momentum is also being shaped by standardized extracts, sublingual tablets for home administration after first-dose supervision, and specialist-led use of component-resolved diagnostics. Biologics are not replacing allergy vaccines; they are sharpening segmentation by identifying patients who need allergen immunotherapy, biologic control, or combination care under evidence-based guidelines.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the allergy vaccine market across discovery, diagnosis, patient selection, and adherence. AI-supported pollen forecasting, electronic health record screening, and digital symptom scoring can help clinicians connect allergen exposure patterns with rhinitis or asthma exacerbations, improving the timing and appropriateness of allergen immunotherapy.

The cumulative impact is strongest where AI supports standardized care pathways rather than replacing clinical judgment. Machine learning can improve trial recruitment, monitor adverse-event signals, predict nonadherence, and personalize dose-escalation support. For manufacturers and providers, the practical opportunity is to use validated AI tools to reduce drop-off during the three-to-five-year immunotherapy course and generate real-world evidence for payers.

Key Regional Insights: Allergy Vaccine Demand by Region

Asia-Pacific is gaining importance as China, India, Japan, South Korea, and Australia face high allergic rhinitis and asthma burdens, rapid urbanization, and growing specialist capacity. North America remains a highly developed allergy vaccine market, supported by FDA-approved sublingual tablets, established allergists, formal practice parameters, and payer scrutiny around outcomes and adherence. Latin America, led by Brazil and Mexico, is expanding gradually as diagnosis improves in urban centers and private respiratory care strengthens.

Europe benefits from strong clinical guideline adoption, national reimbursement variation, and long-standing allergen extract expertise, particularly across Germany, France, Italy, Spain, and the United Kingdom. The Middle East is influenced by desert dust exposure, indoor cooling environments, and high asthma awareness in GCC states, supporting demand for structured allergy diagnosis and immunotherapy access. Africa remains underpenetrated, but urban air pollution, limited specialist access, and unmet respiratory care needs create long-term opportunity for scalable diagnosis, referral, and allergen immunotherapy delivery models.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are shaped by humid climates, house dust mite exposure, urban pollution, and expanding middle-class healthcare access, with demand increasingly linked to specialist availability and diagnostic capacity. The GCC is driven by high indoor allergen exposure, desert dust, air-conditioned living, and investment in specialty care infrastructure. The European Union provides the most structured policy environment, with EMA-aligned quality expectations, pharmacovigilance requirements, and health technology assessment pressure that rewards standardized evidence.

BRICS countries represent scale and diversity: China and India bring large patient pools and rising allergy diagnosis, Brazil adds private allergy care growth, while Russia and South Africa provide regionally important specialist networks with access variability. G7 markets concentrate advanced diagnostics, clinical research, regulated sublingual and subcutaneous immunotherapy adoption, and payer demand for adherence and outcomes data. NATO markets overlap substantially with North America and Europe, creating a resilient base for regulated allergen extracts, digital health tools, quality systems, and supply chain security.

Key Country Insights: Priority Allergy Vaccine Markets

The United States has strong allergist networks, FDA-cleared sublingual immunotherapy tablets, and established subcutaneous immunotherapy practice, while Canada combines public reimbursement variation with high seasonal allergy awareness and specialist-led care. Mexico and Brazil are expanding through private care, urban allergy diagnosis, and growing acceptance of immunotherapy for rhinitis and asthma-linked allergic disease. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from guideline-based care and established allergy services, although reimbursement, extract standardization, and prescribing practices differ by country.

Russia remains a sizable respiratory allergy market with regional access variation and demand concentrated around urban specialist care. China and India offer the largest long-term patient access opportunity because of pollution exposure, urbanization, large allergic rhinitis and asthma populations, and rising specialist availability. Japan and South Korea emphasize high-quality diagnostics, regulated therapies, and adherence-focused care pathways, while Australia has strong pollen monitoring, thunderstorm asthma awareness, allergic rhinitis recognition, and established specialist immunology practice.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize standardized allergen extracts, validated diagnostics, and adherence programs that support the full immunotherapy course. Commercial teams should segment patients by allergen sensitization, asthma comorbidity, symptom severity, exposure profile, and ability to comply with subcutaneous or sublingual regimens.

Manufacturers should invest in real-world evidence, pharmacovigilance, cold-chain reliability where needed, clinician education, and payer-facing health economic models. Providers and distributors should integrate pollen data, digital reminders, shared decision-making tools, and specialist referral pathways to improve initiation, persistence, safety monitoring, and completion rates.

Research Methodology

This executive summary applies a secondary research and expert-validated synthesis approach. Sources considered include WHO respiratory disease statistics, ARIA and WAO allergy guidance, EMA and FDA regulatory references, peer-reviewed climate and pollen research, and publicly available clinical practice recommendations from allergy and immunology societies.

Insights were triangulated across disease burden, regulatory status, care delivery models, regional access conditions, reimbursement context, and technology adoption. Statements avoid unsupported market sizing and emphasize verified directional evidence relevant to allergy vaccine strategy, competitive positioning, patient access, and long-term demand formation.

Conclusion

The allergy vaccine market is moving into a more evidence-driven phase as respiratory allergy prevalence, climate-linked pollen exposure, urban pollution, and demand for durable disease modification converge. Subcutaneous and sublingual immunotherapy remain central because they address immune tolerance rather than only short-term symptom suppression.

Future leadership will depend on standardization, patient selection, adherence, digital support, pharmacovigilance, and region-specific market access. Organizations that combine clinical evidence with scalable delivery models will be best positioned to strengthen relevance in the global allergy vaccine and allergen immunotherapy market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Allergy Vaccine Market, by Vaccine Type
7.1. Monovalent
7.2. Polyvalent
8. Allergy Vaccine Market, by Route Of Administration
8.1. Subcutaneous Immunotherapy
8.1.1. Accelerated Doses
8.1.2. Standard Doses
8.2. Sublingual Immunotherapy
8.2.1. Drops
8.2.2. Tablets
9. Allergy Vaccine Market, by Allergens Targeted
9.1. Perennial Allergens
9.1.1. Animal Dander
9.1.2. Dust Mite
9.2. Seasonal Allergens
9.2.1. Molds
9.2.2. Pollen
10. Allergy Vaccine Market, by Technology
10.1. Recombinant
10.2. Traditional Extract
11. Allergy Vaccine Market, by Patient Age Group
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. Allergy Vaccine Market, by End User
12.1. Clinics
12.2. Home Healthcare
12.3. Hospitals
13. Allergy Vaccine Market, by Distribution Channel
13.1. Hospital Pharmacies
13.2. Online Pharmacies
13.3. Retail Pharmacies
14. Asia-Pacific Allergy Vaccine Market
15. North America Allergy Vaccine Market
16. Latin America Allergy Vaccine Market
17. Europe Allergy Vaccine Market
18. Middle East Allergy Vaccine Market
19. Africa Allergy Vaccine Market
20. ASEAN Allergy Vaccine Market
21. GCC Allergy Vaccine Market
22. European Union Allergy Vaccine Market
23. BRICS Allergy Vaccine Market
24. G7 Allergy Vaccine Market
25. NATO Allergy Vaccine Market
26. United States Allergy Vaccine Market
27. Canada Allergy Vaccine Market
28. Mexico Allergy Vaccine Market
29. Brazil Allergy Vaccine Market
30. United Kingdom Allergy Vaccine Market
31. Germany Allergy Vaccine Market
32. France Allergy Vaccine Market
33. Russia Allergy Vaccine Market
34. Italy Allergy Vaccine Market
35. Spain Allergy Vaccine Market
36. China Allergy Vaccine Market
37. India Allergy Vaccine Market
38. Japan Allergy Vaccine Market
39. Australia Allergy Vaccine Market
40. South Korea Allergy Vaccine Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. Adamis Pharmaceuticals Corporation
42.2. ALK-Abelló A/S
42.3. Allergy Therapeutics plc
42.4. Anergis SA
42.5. Biomay AG
42.6. Boehringer Ingelheim International GmbH
42.7. Circassia Group plc
42.8. CSL Limited
42.9. DESENTUM OY
42.10. HAL Allergy B.V.
42.11. Inmunotek S.L.
42.12. Jubilant HollisterStier LLC
42.13. Laboratorios LETI, S.L.U.
42.14. LETI Pharma, S.L.U.
42.15. Merck KGaA
42.16. Novartis International AG
42.17. Pfizer Inc.
42.18. Prota Therapeutics Pty Ltd
42.19. Regeneron Pharmaceuticals, Inc.
42.20. Roxall Medizin GmbH
42.21. Sanofi S.A.
42.22. Stallergenes Greer International AG
42.23. WOLW Biopharmaceutical Co., Ltd.
List of Figures
FIGURE 1. GLOBAL ALLERGY VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ALLERGY VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ALLERGY VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ALLERGY VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ALLERGY VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ALLERGY VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 27. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. EUROPE ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. EUROPE ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. ASEAN ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. ASEAN ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. GCC ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. GCC ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. BRICS ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. BRICS ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. G7 ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. G7 ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. NATO ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. NATO ALLERGY VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. UNITED STATES ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. CANADA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. MEXICO ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. BRAZIL ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. GERMANY ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. FRANCE ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. ITALY ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. SPAIN ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CHINA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. INDIA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. JAPAN ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. AUSTRALIA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SOUTH KOREA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ALLERGY VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ALLERGY VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ALLERGY VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MONOVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MONOVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MONOVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL POLYVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL POLYVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL POLYVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ACCELERATED DOSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ACCELERATED DOSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ACCELERATED DOSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL STANDARD DOSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL STANDARD DOSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL STANDARD DOSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DROPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DROPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DROPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PERENNIAL ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PERENNIAL ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PERENNIAL ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANIMAL DANDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANIMAL DANDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANIMAL DANDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DUST MITE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DUST MITE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DUST MITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SEASONAL ALLERGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SEASONAL ALLERGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SEASONAL ALLERGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MOLDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MOLDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MOLDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL POLLEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL POLLEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL POLLEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL TRADITIONAL EXTRACT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TRADITIONAL EXTRACT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TRADITIONAL EXTRACT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 128. EUROPE ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 130. EUROPE ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 131. EUROPE ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 132. EUROPE ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 133. EUROPE ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 135. EUROPE ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 136. EUROPE ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. EUROPE ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150. AFRICA ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 152. AFRICA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 154. AFRICA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 155. AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 156. AFRICA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 157. AFRICA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 158. AFRICA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 159. AFRICA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 160. AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. AFRICA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. ASEAN ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 163. ASEAN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 164. ASEAN ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. ASEAN ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 166. ASEAN ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 167. ASEAN ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 168. ASEAN ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 169. ASEAN ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 170. ASEAN ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 171. ASEAN ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 172. ASEAN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. ASEAN ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. GCC ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 175. GCC ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 176. GCC ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. GCC ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 178. GCC ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 179. GCC ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 180. GCC ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 181. GCC ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 182. GCC ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 183. GCC ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. GCC ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. GCC ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. BRICS ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 199. BRICS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 200. BRICS ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. BRICS ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 202. BRICS ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 203. BRICS ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 204. BRICS ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 205. BRICS ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 206. BRICS ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 207. BRICS ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 208. BRICS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. BRICS ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. G7 ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 211. G7 ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 212. G7 ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. G7 ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 214. G7 ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 215. G7 ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 216. G7 ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 217. G7 ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 218. G7 ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 219. G7 ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 220. G7 ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. G7 ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. NATO ALLERGY VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 223. NATO ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 224. NATO ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. NATO ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 226. NATO ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 227. NATO ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 228. NATO ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 229. NATO ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 230. NATO ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 231. NATO ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 232. NATO ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. NATO ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. CANADA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 247. CANADA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 248. CANADA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. CANADA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 250. CANADA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 251. CANADA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 252. CANADA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 253. CANADA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 254. CANADA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 255. CANADA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 256. CANADA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. CANADA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. MEXICO ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 259. MEXICO ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 260. MEXICO ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. MEXICO ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 262. MEXICO ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 263. MEXICO ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 264. MEXICO ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 265. MEXICO ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 266. MEXICO ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 267. MEXICO ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 268. MEXICO ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 269. MEXICO ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 270. BRAZIL ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. BRAZIL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 272. BRAZIL ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. BRAZIL ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 274. BRAZIL ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 275. BRAZIL ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 276. BRAZIL ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 277. BRAZIL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 278. BRAZIL ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 279. BRAZIL ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 280. BRAZIL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. BRAZIL ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 294. GERMANY ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 295. GERMANY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 296. GERMANY ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 297. GERMANY ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 298. GERMANY ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 299. GERMANY ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 300. GERMANY ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 301. GERMANY ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 302. GERMANY ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 303. GERMANY ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 304. GERMANY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 305. GERMANY ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 306. FRANCE ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 307. FRANCE ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 308. FRANCE ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. FRANCE ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 310. FRANCE ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 311. FRANCE ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 312. FRANCE ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 313. FRANCE ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 314. FRANCE ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 315. FRANCE ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 316. FRANCE ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 317. FRANCE ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 318. RUSSIA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 319. RUSSIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 320. RUSSIA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 321. RUSSIA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 322. RUSSIA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 323. RUSSIA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 324. RUSSIA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 325. RUSSIA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 326. RUSSIA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 327. RUSSIA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 328. RUSSIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 329. RUSSIA ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 330. ITALY ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 331. ITALY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 332. ITALY ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 333. ITALY ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 334. ITALY ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 335. ITALY ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 336. ITALY ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 337. ITALY ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 338. ITALY ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 339. ITALY ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 340. ITALY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 341. ITALY ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 342. SPAIN ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 343. SPAIN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 344. SPAIN ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 345. SPAIN ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 346. SPAIN ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 347. SPAIN ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 348. SPAIN ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 349. SPAIN ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 350. SPAIN ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 351. SPAIN ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 352. SPAIN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 353. SPAIN ALLERGY VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 354. CHINA ALLERGY VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 355. CHINA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 356. CHINA ALLERGY VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 357. CHINA ALLERGY VACCINE MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 358. CHINA ALLERGY VACCINE MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 359. CHINA ALLERGY VACCINE MARKET SIZE, BY ALLERGENS TARGETED, 2018-2032 (USD MILLION)
TABLE 360. CHINA ALLERGY VACCINE MARKET SIZE, BY PERENNIAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 361. CHINA ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGENS, 2018-2032 (USD MILLION)
TABLE 362. CHINA ALLERGY VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 363. CHINA ALLERGY VACCINE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLIO

Companies Mentioned

The companies featured in this Allergy Vaccine market report include:
  • Adamis Pharmaceuticals Corporation
  • ALK‑Abelló A/S
  • Allergy Therapeutics plc
  • Anergis SA
  • Biomay AG
  • Boehringer Ingelheim International GmbH
  • Circassia Group plc
  • CSL Limited
  • DESENTUM OY
  • HAL Allergy B.V.
  • Inmunotek S.L.
  • Jubilant HollisterStier LLC
  • Laboratorios LETI, S.L.U.
  • LETI Pharma, S.L.U.
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Prota Therapeutics Pty Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Roxall Medizin GmbH
  • Sanofi S.A.
  • Stallergenes Greer International AG
  • WOLW Biopharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.79 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.9 Billion
Compound Annual Growth Rate13.5%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Allergy Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034 - Product Image

Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From
Allergy Immunotherapy Market by Allergy Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Treatment Type, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Allergy Immunotherapy Market by Allergy Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Treatment Type, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Allergy Vaccines Market - Global Strategic Business Report - Product Image

Allergy Vaccines Market - Global Strategic Business Report

  • Report
  • 481 Pages
  • Global
From
Peanut Allergy Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peanut Allergy Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Allergy Vaccine Market

The Allergy Vaccine market is a subset of the Vaccines market, which is composed of products designed to prevent or reduce the severity of infectious diseases. Allergy Vaccines are specifically designed to reduce the severity of allergic reactions, such as hay fever, asthma, and food allergies. These vaccines are typically administered through a series of injections, which can be tailored to the individual patient's needs. Allergy Vaccines are becoming increasingly popular as a way to reduce the burden of allergic reactions, and are being used in both adults and children. They are also being used in combination with other treatments, such as antihistamines and immunotherapy, to provide a more comprehensive approach to managing allergies. Some companies in the Allergy Vaccine market include ALK-Abello, Stallergenes Greer, Allergy Therapeutics, and DBV Technologies. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.